

Bruno Vincenzi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1543980/bruno-vincenzi-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148 papers	2,185 citations	26 h-index	41 g-index
154 ext. papers	2,829 ext. citations	4.9 avg, IF	4.64 L-index

#	Paper	IF	Citations
148	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
147	Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.. <i>Journal of Bone Oncology</i> , 2022 , 34, 100422	4.5	0
146	Germline Variants in Adult Patients With -Mutant Gastrointestinal Stromal Tumor.. <i>Frontiers in Oncology</i> , 2021 , 11, 778461	5.3	2
145	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103567	7	13
144	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
143	S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. <i>Chemotherapy</i> , 2021 , 66, 161-168	3.2	
142	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 2021 , 9,		11
141	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021 , 10, 2645-2659	4.8	8
140	Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. <i>Thoracic Cancer</i> , 2021 , 12, 1791-1792	3.2	
139	Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e137-e138	4.9	
138	Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. <i>Oncologist</i> , 2021 , 26, e710-e714	5.7	3
137	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021 , 13,	6.6	5
136	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021 , 17, 2923-2939	3.6	5
135	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
134	Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma. <i>Biology</i> , 2021 , 10,	4.9	1
133	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 87	5.4	7
132	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 165, 103436	7	28

131	Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. <i>Oncogene</i> , 2021 , 40, 1284-1299	9.2	16
130	Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms.. <i>Frontiers in Oncology</i> , 2021 , 11, 789885	5.3	0
129	Steroid-refractory immune related hepatitis may hide viral re-activation. <i>Future Science OA</i> , 2020 , 6, FSO614	6.14	1
128	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	2
127	Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. <i>European Thyroid Journal</i> , 2020 , 9, 157-161	4.2	3
126	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR/SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020 , 10, 504	5.3	7
125	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 95	12.8	69
124	Facing SARS-CoV-2 outbreak in immunotherapy era. <i>Future Oncology</i> , 2020 , 16, 1475-1485	3.6	8
123	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020 , 5,	6	5
122	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
121	Neurokinin-1 antagonist orvepitant for EGFR-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial. <i>BMJ Open</i> , 2020 , 10, e030114	3	4
120	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020 , 25, e1777-e1784	5.7	10
119	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 319-326	5.4	8
118	Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e105-e106	8.9	10
117	Prognostic and predictive factors in pancreatic cancer. <i>Oncotarget</i> , 2020 , 11, 924-941	3.3	24
116	Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 420-420	2.2	
115	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 493-501	4.9	5
114	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020 , 5,	6	8

113	Recent Advances in Desmoid Tumor Therapy. <i>Cancers</i> , 2020 , 12,	6.6	3
112	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Cancer Discovery</i> , 2020 ,	24.4	96
111	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
110	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020 , 14, 1179554920946693	1.8	3
109	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1261-1274	5.4	4
108	Definition of a Novel Plasmid-Based Gene Transfection Protocol of Mammalian Skeletal Muscles by Means of In Vivo Electroporation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
107	Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study. <i>Oncology</i> , 2020 , 98, 893-896	3.6	1
106	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
105	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919874653	5.4	18
104	Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for HodgkinB and Non-Hodgkin Lymphoma. <i>Chemotherapy</i> , 2019 , 64, 36-41	3.2	4
103	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919848872	5.4	19
102	Unexpected benefit from an old metronomic chemotherapy regimen in advanced chordoma. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	2
101	New frontiers in the medical management of gastrointestinal stromal tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919841946	5.4	21
100	Gain of FGF4 is a frequent event in KIT/PDGFR/SDH/RAS-P WT GIST. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 636-642	5	12
99	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019 , 11,	6.6	27
98	PDGFR inhibition in soft-tissue sarcomas: Have we gotten it all wrong?. <i>EBioMedicine</i> , 2019 , 40, 37-38	8.8	2
97	Adjuvant electrochemotherapy with bleomycin and cisplatin combination for canine soft tissue sarcomas: A study of 30 cases. <i>Open Veterinary Journal</i> , 2019 , 9, 88-93	1	14
96	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. <i>Chemotherapy</i> , 2019 , 64, 105-109	3.2	5

95	Anticancer activity of "Trigno M", extract of <i>Prunus spinosa</i> drupes, against in vitro 3D and in vivo colon cancer models. <i>Biomedicine and Pharmacotherapy</i> , 2019 , 118, 109281	7.5	10
94	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919877725	5.4	8
93	Cabozantinib and apixaban: an hitherto unreported interaction. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 22	7.8	5
92	Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e22545-e22545	2.2	2
91	Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 510-510	2.2	1
90	Upper eyelid Merkel cell carcinoma treated with neoadjuvant chemotherapy and surgical excision. <i>Archives of Craniofacial Surgery</i> , 2019 , 20, 121-125	1.3	2
89	Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11065-11065	2.2	1
88	Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e22540-e22540	2.2	
87	Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11053-11053	2.2	
86	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11032-11032	2.2	
85	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16109-e16109	2.2	
84	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019 , 24, e536-e541	5.7	12
83	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. <i>Cellular Immunology</i> , 2019 , 343, 103753	4.4	108
82	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018 , 95, 1-7	3.6	5
81	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
80	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11574-11574	2.2	6
79	Cetuximab administered once every second week to patients with advanced head and neck cancer: Safety and feasibility of maintenance schedule after first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18006-e18006	2.2	0
78	An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e23502-e23502	2.2	

77	FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11556-11556	2.2	1
76	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
75	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918794623	5.4	15
74	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017 , 15, 553-562	6.6	34
73	Determinants of bone specific metastasis in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 59-66	7	14
72	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 118, 1-6	7	10
71	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. <i>British Journal of Cancer</i> , 2017 , 117, 340-346	8.7	16
70	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 731-739	5.4	14
69	Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. <i>Oncotarget</i> , 2017 , 8, 20113-20121	3.3	29
68	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11065-11065	2.2	2
67	BMI as a risk factor for toxicities in patients with advanced soft tissue sarcoma treated with trabectedin.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e22517-e22517	2.2	
66	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11038-11038	2.2	
65	Numerical, dimensional or mixed progression disease to imatinib as prognostic factor in patients with metastatic GIST.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11040-11040	2.2	
64	Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11042-11042	2.2	1
63	M1-polarized macrophages as predictor of poor response to trabectedin treatment in myxoid liposarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e22537-e22537	2.2	1
62	Biological effects of cabozantinib on bone microenvironment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23004-e23004	2.2	1
61	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016 , 7, 69412-69419	3.3	10
60	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10

59	Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11062-11062	2.2	
58	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1219-38	4.1	33
57	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
56	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 637-517	5.1	5
55	Classic Kaposi Sarcoma: to treat or not to treat?. <i>BMC Research Notes</i> , 2015 , 8, 138	2.3	7
54	Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 971-6	3.5	8
53	Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. <i>Scientific Reports</i> , 2015 , 5, 12077	4.9	1
52	Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. <i>Breast Cancer Research</i> , 2015 , 17, 121	8.3	25
51	Pazopanib and pancreatic toxicity: a case report. <i>BMC Research Notes</i> , 2015 , 8, 196	2.3	8
50	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 206-19	7	20
49	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
48	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0133488	3.7	76
47	HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer. <i>Histology and Histopathology</i> , 2015 , 30, 707-14	1.4	7
46	Deregulation of dicer and mir-155 expression in liposarcoma. <i>Oncotarget</i> , 2015 , 6, 10586-91	3.3	17
45	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015 , 6, 12520-8	3.3	41
44	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27
43	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22075-e22075	2.2	
42	Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15246-e15246	2.2	

41	Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10553-10553	2.2	1
40	MicroRNAs and bone metastasis: a new challenge. <i>Molecules</i> , 2014 , 19, 10115-28	4.8	15
39	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10515-10515	2.2	1
38	The potential diagnostic role of procalcitonin for bacteremia in a large cohort of solid cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20664-e20664	2.2	
37	Activity of chemotherapy in a series of patients with locally advanced or metastatic pleomorphic rhabdomyosarcoma: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10592-10592	2.2	
36	Multicenter retrospective analysis of 31 patients with aggressive angiomyxoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10585-10585	2.2	
35	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10572-10572	2.2	
34	Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. <i>Clinical Sarcoma Research</i> , 2013 , 3, 6	2.5	16
33	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. <i>Supportive Care in Cancer</i> , 2013 , 21, 1313-9	3.9	46
32	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2013 , 49, 1501-8	7.5	15
31	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026	3.7	52
30	Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10568-10568	2.2	2
29	Effect of cholesterol and triglyceride increases on time to progression in renal clear cell cancer patients treated with everolimus.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15528-e15528	2.2	
28	PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <i>Journal of Cellular Physiology</i> , 2012 , 227, 927-33	7	5
27	PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/anthracycline-based first line therapy. <i>Journal of Cellular Physiology</i> , 2012 , 227, 1657-62	7	3
26	The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. <i>Supportive Care in Cancer</i> , 2012 , 20, 135-9	3.9	20
25	Evidence-based guidelines: Improving AGREement on consistence evaluation. <i>Journal of Bone Oncology</i> , 2012 , 1, 30-4	4.5	
24	Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. <i>Lancet Oncology, The</i> , 2012 , 13, 1020-4	21.7	87

23	Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1685-705	5.9	4
22	The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 345-9	4.1	13
21	Aprepitant for erlotinib-induced pruritus. <i>New England Journal of Medicine</i> , 2010 , 363, 397-8	59.2	71
20	New therapies in soft tissue sarcoma. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 237-48	3.7	25
19	Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. <i>Pharmacogenomics</i> , 2010 , 11, 865-78	2.6	18
18	Cetuximab: from bench to bedside. <i>Current Cancer Drug Targets</i> , 2010 , 10, 80-95	2.8	93
17	Aprepitant against pruritus in patients with solid tumours. <i>Supportive Care in Cancer</i> , 2010 , 18, 1229-30	3.9	47
16	PML down-regulation in soft tissue sarcomas. <i>Journal of Cellular Physiology</i> , 2010 , 224, 644-8	7	5
15	Target therapy in gastrointestinal tract sarcoma: What is new?. <i>World Journal of Gastrointestinal Oncology</i> , 2010 , 2, 1-4	3.4	
14	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 945-9	5.4	12
13	Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. <i>Cancer</i> , 2009 , 115, 4849-56	6.4	27
12	Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 455-65		14
11	Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. <i>Clinical Cancer Research</i> , 2008 , 14, 4219-24	12.9	46
10	The biological properties of cetuximab. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 93-106	7	96
9	Bisphosphonates: from preclinical evidence to survival data in the oncologic setting. <i>Oncology Reviews</i> , 2007 , 1, 141-151	4.3	
8	Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. <i>Pharmacogenomics</i> , 2007 , 8, 319-27	2.6	33
7	Taxanes in adjuvant chemotherapy for early breast cancer. <i>Women's Health</i> , 2006 , 2, 323-5	3	
6	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 665-83	3.7	1

5	Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 144-51	3.5	106
4	Predictive factors for response to chemotherapy in colorectal cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 52, 45-60	7	8
3	Thrombophilic Genetic Mutations Have No Impact in the Pathogenesis of Thromboembolism in Gastro-Intestinal Cancer Patients.. <i>Blood</i> , 2004 , 104, 3518-3518	2.2	
2	Cytokines Behaviour in Multiple Myeloma during Zoledronic Acid Treatment.. <i>Blood</i> , 2004 , 104, 4913-4913	2.2	
1	Physiologic Inhibitors of Coagulation, Thrombophilic Acquired Factors and Venous Thromboembolism in Gastrointestinal Cancer Patients.. <i>Blood</i> , 2004 , 104, 4044-4044	2.2	